Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Celecoxib (AN) TM
Active ingredients: celecoxib
What it is used for
Celecoxib is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,Celecoxib is indicated for the treatment of primary dysmenorrhoea in adults.,Celecoxib is indicated for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Shelf lifetime is 42 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Opaque, white capsules with 2 gold bands and marked "200" on the body.
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient celecoxib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Pain medication - BluePages
Find out if painkillers are likely to help.
Read more on e-hub Web Services - Australian National University (ANU) website
Coxibs and arthritis pain and inflammation - myDr.com.au
A class of drugs called COX-2 inhibitors, or coxibs, have been designed to help relieve pain and inflammation in osteoarthritis and rheumatoid arthritis.
Read more on myDr website
Non-steroidal anti-inflammatory drugs (NSAIDS) information | myVMC
Non-steroidal anti-inflammatory drugs (NSAIDS) like ibuprofin are used to treat pain and inflammation and reduce temperature in fever.
Read more on myVMC – Virtual Medical Centre website
Aspirin-induced asthma (NSAIDS and asthma) information | myVMC
Aspirin-induced asthma is characterised by aggressive inflammation of the airways, that is, worsening asthma, after ingestion of aspirin or NSAIDs.
Read more on myVMC – Virtual Medical Centre website
Allergic reactions to aspirin and other pain killers - Australasian Society of Clinical Immunology and Allergy (ASCIA)
Aspirin has long been used to reduce pain from inflammation (redness and swelling) and injury, as well as fever. Although it was originally isolated from plants in the early 1800's, aspirin is now made synthetically. A number of similar synthetic non-steroidal anti-inflammatory drugs (NSAIDS) have also been introduced.
Read more on ASCIA – Australasian Society of Clinical Immunology and Allergy website
Medications - non-steroidal anti-inflammatory drugs - Better Health Channel
Non-steroidal anti-inflammatory medicines should always be used cautiously and for the shortest time possible.
Read more on Better Health Channel website
Kidney Cysts
Cystic kidney disease causes pockets of clear, watery fluid (cysts) to form in the kidneys.
Read more on Kidney Health Australia website
Top results
Celecoxib for treating rheumatoid arthritis | Cochrane
This review included five randomized controlled trials with a total of 4465 participants. The evidence reviewed suggests that celecoxib controls the symptoms of rheumatoid arthritis (RA) to a similar degree to that of the active comparators examined (naproxen, diclofenac and ibuprofen). When compared to placebo, the percentage of patients showing improvement by four weeks were 42/82 (51%) in the twice-daily celecoxib 200mg group and 43/82 (52%) in the twice-daily celecoxib 400mg group; these were significantly different from the placebo group in which 25/85 (29%) improved. At six months this study found a reduced rate of upper gastrointestinal complications with celecoxib but there is also evidence to suggest that these benefits may not be evident in the long-term and that celecoxib offers no additional benefit in patients who are also receiving cardio-prophylactic low dose aspirin.
Read more on Cochrane (Australasian Centre) website
Single-dose oral celecoxib for postoperative pain | Cochrane
Read more on Cochrane (Australasian Centre) website
Tolerability of selective cyclooxygenase 2 (COX-2) inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease | Cochrane
Tolerability of selective cyclooxygenase 2 (COX-2) inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease
Read more on Cochrane (Australasian Centre) website
Single dose oral etodolac for acute postoperative pain in adults | Cochrane
Etodolac 200 mg provides a high level of pain relief in about 40% of those with moderate or severe acute postoperative pain. This is fewer than one would expect to see of the same level of pain relief with standard doses of ibuprofen, naproxen and diclofenac. Higher doses of etodolac may be more effective There were no more adverse events than with placebo in these single dose studies.
Read more on Cochrane (Australasian Centre) website
Acetaminophen for osteoarthritis | Cochrane
How well does acetaminophen work and compare to anti-inflammatories to treat osteoarthritis and is it safe?
Read more on Cochrane (Australasian Centre) website
Pain management for rheumatoid arthritis with cardiovascular or renal comorbidity | Cochrane
This summary of a Cochrane review presents what we know from research about the safety of using pain-relieving drugs in people with rheumatoid arthritis who also have either heart or kidney disease, or both.
Read more on Cochrane (Australasian Centre) website
Pain in patients with inflammatory arthritis and gastrointestinal or liver problems | Cochrane
This summary of a Cochrane review presents what we know from research about the effect of pain relieving drugs for people with inflammatory arthritis plus stomach or gut disease, or liver disease.
Read more on Cochrane (Australasian Centre) website
Rofecoxib for osteoarthritis | Cochrane
Editor's note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke. Further information is available at www.vioxx.com.
Read more on Cochrane (Australasian Centre) website
The treatment of cervical pre-cancer (CIN) with anti-inflammatory agents to induce regression and prevent the progression to cervical cancer | Cochrane
Read more on Cochrane (Australasian Centre) website
Combining two or more drugs vs one drug for pain control in inflammatory arthritis | Cochrane
This summary of a Cochrane review presents what we know from research about the effect of a combination of two pain relieving drugs for pain control in inflammatory arthritis (IA).
Read more on Cochrane (Australasian Centre) website
